Viking Therapeutics, INC. (VKTX) SEC Filings — 2025

Filings

• Viking's R&D Surge Drives 171% Net Loss Increase to $202M — 10-Q · Oct 23, 2025
• Viking Therapeutics Files 8-K on Financials — 8-K · Oct 22, 2025
• Viking Therapeutics Files 8-K Report — 8-K · Aug 19, 2025
• Viking Therapeutics' Losses Widen Amid R&D Surge, Cash Position Strong — 10-Q · Jul 23, 2025
• Viking Therapeutics Files 8-K on Shareholder Votes & Exhibits — 8-K · May 27, 2025
• Viking Therapeutics Files Q1 2025 10-Q — 10-Q · Apr 24, 2025
• Viking Therapeutics Files 8-K: Auditor Change — 8-K · Apr 23, 2025
• Viking Therapeutics DEF 14A: Executive Compensation Details — DEF 14A · Apr 8, 2025
• Viking Therapeutics Files 8-K on Material Agreement — 8-K · Mar 11, 2025
• Viking Therapeutics Files 2024 10-K — 10-K · Feb 26, 2025
• Viking Therapeutics Files 8-K on Financials — 8-K · Feb 5, 2025